BIL 06v

Drug Profile

BIL 06v

Alternative Names: BIL-06v

Latest Information Update: 07 Jun 2016

Price : $50

At a glance

  • Originator Biosceptre International; Peptech UK
  • Developer Biosceptre International
  • Class Peptide vaccines
  • Mechanism of Action Purinergic P2X7 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 May 2016 Preclinical trials in Cancer in United Kingdom (Parenteral) before May 2016
  • 31 May 2016 Biosceptre plans a phase I trial of BIL 06v for Solid tumours in the United Kingdom
  • 01 Nov 2003 Early research in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top